Horizon Fuel Cell Technologies

908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System

Retrieved on: 
Monday, November 6, 2023
Other Health, Other Science, Pharmaceutical, Research, Software, Medical Devices, Internet, Electronic Design Automation, Genetics, Data Management, Professional Services, Science, Technology, General Health, Data Analytics, Biotechnology, Health, Health Technology, TrafFix Devices, Inc. v. Marketing Displays, Inc., Horizon Fuel Cell Technologies, MAVEN, MASS, Exosome, Risk, Automation, Medical device, Vaccine, Terumo

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT’s Quantum Flex Cell Expansion System.

Key Points: 
  • 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT’s Quantum Flex Cell Expansion System.
  • Cell and gene therapy developers are increasingly looking to automation to improve manufacturing efficiency, simplify workflows and reduce costs.
  • “Combining our Quantum Flex platform with 908 Devices’ on-line monitoring will help cell therapy manufacturers reduce time-consuming manual steps that increase manufacturing costs and risks,” said Kathie Schneider, Director, Global Commercial Lead, Cell Therapy Technologies at Terumo BCT.
  • “We continue to collaborate with industry experts to further enhance our solution offering to solve industry challenges.”

Osmolality Analysis in Bioprocessing: From Theory to Practice, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 6, 2023
Molality, Osmotic pressure, Glycoprotein, Cell, Horizon Fuel Cell Technologies, PAT, Glycosylation, Growth, A-DNA, QC, Immunoglobulin G, Buffer, CHO, Fine chemical, Medical imaging

TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production. Osmolality is described as the measurement of the contribution of all the dissolved solutes to the osmotic pressure of a solution. In biopharma, osmolality is usually used as a critical quality control (QC) check for cell culture media, buffers and formulated drug products. It is also used as a critical process parameter during upstream cell culture and downstream filtration.

Key Points: 
  • Attendees will learn about using osmolality analysis in Chinese hamster ovary (CHO) cell health studies.
  • The featured speakers will discuss current uses and future potential for osmolality analysis at the upstream and downstream stages of bioprocessing.
  • TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production.
  • Join this webinar to gain insights into osmolality in correlation with IgG production in a media development project.

EQS-News: ElringKlinger appoints Thomas Jessulat as CEO and names Dirk Willers as a new member of the Management Board

Retrieved on: 
Thursday, September 28, 2023
Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Human resources, Partnership, University, Korea Engineering Plastics, Supervisory board, Aftermarket, ElringKlinger, MBA, Daimler, Spokesperson, Marketing, Advanced Battery Technologies, Originality, Mercedes-Benz Group, Comment, Engineering, Supervision, Communication, ISIN, CFO, Horizon Fuel Cell Technologies, University of Bayreuth, University of Nebraska system, Security (finance), Management

He had most recently held the position of Spokesperson of the Management Board on an interim basis.

Key Points: 
  • He had most recently held the position of Spokesperson of the Management Board on an interim basis.
  • In addition, the former head of the Aftermarket segment, Dirk Willers, was newly appointed to the Management Board.
  • Dirk Willers restructured our Aftermarket business from top to bottom and, in particular, realigned Sales to create a more powerful presence.
  • Before joining ElringKlinger in 2015, the 49-year-old business graduate held senior management positions at Daimler AG for over 12 years.

EQS-News: New EKPO order marks first strategic step into the electrolysis market

Retrieved on: 
Wednesday, August 30, 2023
Partnership, Electrolysis, Hydrogen, ElringKlinger, Research, Gesellschaft mit beschränkter Haftung, Marketing, PEM, Water, Horizon Fuel Cell Technologies, Renewable energy

Dettingen/Erms (Germany), August 30, 2023 +++ EKPO Fuel Cell Technologies GmbH (EKPO) and H-TEC SYSTEMS GmbH have entered into a contractual agreement for the development of stack components for PEM electrolyzers.

Key Points: 
  • Dettingen/Erms (Germany), August 30, 2023 +++ EKPO Fuel Cell Technologies GmbH (EKPO) and H-TEC SYSTEMS GmbH have entered into a contractual agreement for the development of stack components for PEM electrolyzers.
  • EKPO will contribute its expertise in development, large-scale production of stack components, and defect reduction in the context of highly automated operations.
  • The development, which has already started, and the production of the prototypes to be supplied under the agreement will take place in Germany.
  • We look forward to advancing our series production and the quality of our products in cooperation with EKPO."

Terumo Blood and Cell Technologies' Reveos® Automated Whole Blood Processing System Cleared by FDA for U.S. Commercial Use

Retrieved on: 
Tuesday, August 1, 2023
RBC, Food and Drug Administration, Cancer, Apheresis, Terumo, Plasma, Patient, Investment, Collection, Blood, Horizon Fuel Cell Technologies, FDA, Trauma, Food, Medical device, Blood product, Pharmaceutical industry

LAKEWOOD, Colo., Aug. 1, 2023 /PRNewswire/ -- Terumo Blood and Cell Technologies (Terumo BCT) announces U.S. Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System, the first whole blood automation device available in the U.S. that processes whole blood into platelets and other components in a single centrifugation cycle. Automated processing of whole blood on the Reveos system, the only device of its kind globally, will enhance the blood and platelet supply for patients in the U.S.

Key Points: 
  • [2] FDA's clearance of the automated Reveos system gives blood centers the added capacity to collect platelets from existing whole blood donations efficiently.
  • In Reveos, Terumo BCT brings to the U.S. a platform with an established track record following deployment in 52 countries over the past decade.
  • Reveos is the only automated device to process whole blood into platelets, plasma and red blood cell (RBC) components in a single centrifugation cycle.
  • By automating whole blood processing, Reveos can reduce the working hours needed by laboratory staff by up to 30%.

EQS-News: EKPO supplies fuel cell stacks for cruise ship

Retrieved on: 
Tuesday, July 4, 2023
Electricity, Horizon Fuel Cell Technologies, CO2, Cell, Hydrogen, Gesellschaft mit beschränkter Haftung, Electric battery

Dettingen/Erms (Germany), July 04, 2023 +++ EKPO Fuel Cell Technologies GmbH (EKPO) has secured a contract from an international cruise company.

Key Points: 
  • Dettingen/Erms (Germany), July 04, 2023 +++ EKPO Fuel Cell Technologies GmbH (EKPO) has secured a contract from an international cruise company.
  • The agreement covers the supply of NM12 Single fuel cell stacks for initially one cruise ship operated by the global cruise line.
  • Dr. Gernot Stellberger, Managing Director of EKPO Fuel Cell Technologies, commented as follows: "The agreement has tremendous potential for the future and confirms our commitment to help shape the development of sustainable and eco-friendly shipping with our fuel cell stacks.
  • EKPO is supplying NM12 Single stacks for the cruise ship's fuel cell propulsion system.

America’s Blood Centers Announces Inaugural Blood Advocacy Week to Promote the Value of Blood to Patients, Communities, and our Healthcare System

Retrieved on: 
Wednesday, April 5, 2023
National Hemophilia Foundation, Gulf Coast Regional Blood Center, Health care, Fresenius (company), Thrive, Capitol Hill, Civil Air Patrol, Food, America's Blood Centers, Vitalant, LifeSouth Community Blood Centers, Whitman-Walker Health, Blood Assurance, Organization, Hospital, Patient, Korea Disease Control and Prevention Agency, ABC, Horizon Fuel Cell Technologies, Regulation of tobacco by the U.S. Food and Drug Administration, GLAAD, New Orleans, Social media, Pharmaceutical industry, Medical device, Blood

Washington, DC, April 05, 2023 (GLOBE NEWSWIRE) -- America’s Blood Centers (ABC), the national organization of community-based, independent blood centers that supply 60 percent of the nation’s blood supply, today announced the inaugural Blood Advocacy Week occurring April 24th-28th.

Key Points: 
  • Washington, DC, April 05, 2023 (GLOBE NEWSWIRE) -- America’s Blood Centers (ABC), the national organization of community-based, independent blood centers that supply 60 percent of the nation’s blood supply, today announced the inaugural Blood Advocacy Week occurring April 24th-28th.
  • Dozens of diverse partners have signed on to help promote the value of blood through taking part in Blood Advocacy Week.
  • They are being joined by community blood centers across the country, including Blood Assurance, Carter BloodCare, Community Blood Center (Appleton), Community Blood Center-Dayton, the Blood Center (New Orleans), Gulf Coast Regional Blood Center, Houchin Community Blood Bank, LIFELINE Blood Services, LifeServe Blood Center, LifeSouth Community Blood Centers, MEDIC Regional Blood Center, Miller-Keystone Blood Center, Rock River Valley Blood Center, San Diego Blood Bank, Shepeard Community Blood Center, South Texas Blood and Tissue, The Blood Connection, Versiti, and Vitalant.
  • Founded in 1962, America’s Blood Centers is the national organization bringing together community-based, independent blood centers.

Terumo Blood and Cell Technologies' IMUGARD Platelet Pooling Set Cleared by FDA

Retrieved on: 
Thursday, February 16, 2023
World Blood Donor Day, Blood, Transplant, Food and Drug Administration, Utilization, Bone marrow, Patient, Horizon Fuel Cell Technologies, Cell, Food, FDA, Blood product

LAKEWOOD, Colo., Feb. 16, 2023 /PRNewswire/ -- Today, Terumo Blood and Cell Technologies announces U.S. Food and Drug Administration (FDA) clearance and official launch of its IMUGARD® WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days.[1] IMUGARD is the first platelet pooling set approved for seven-day storage in the U.S. and provides an alternate source of platelet supply at a time when demand continues to increase while the supply remains challenged by the lack of blood donors.

Key Points: 
  • IMUGARD to Help Strained U.S. Platelet Supply Meet Growing Need
    LAKEWOOD, Colo., Feb. 16, 2023 /PRNewswire/ -- Today, Terumo Blood and Cell Technologies announces U.S. Food and Drug Administration (FDA) clearance and official launch of its IMUGARD® WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days.
  • Terumo Blood and Cell Technologies is a medical technology company that makes products that collect, process and separate blood and cells.
  • IMUGARD now gives blood centers another product choice to help them recoup platelets from whole blood donations.
  • "We continue to invest in innovations that help blood centers to positively impact patients," says Chetan Makam, General Manager, Global Blood Solutions, Terumo Blood and Cell Technologies.

Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke

Retrieved on: 
Thursday, January 19, 2023
Health, Stem Cells, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, IND, National Institutes of Health Stroke Scale, Gene expression, MMSE, UCI, University, Mercy Gilbert Medical Center, SAFETY, AND, NIHSS, B cell, Depression, Cell proliferation, Rankine scale, Atlantic Film Festival, Rehabilitation, FDA, University of California, Horizon Fuel Cell Technologies, Patient, UCSD, Stroke, Clinical trial, Stem cell, GDS, Pharmaceutical industry, Safety

Stemedica plans to initiate a Phase IIb/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of a single intravenous injection of allogeneic mesenchymal stem cells to subjects with ischemic stroke.

Key Points: 
  • Stemedica plans to initiate a Phase IIb/III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of a single intravenous injection of allogeneic mesenchymal stem cells to subjects with ischemic stroke.
  • Stemedica successfully completed a Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke in patients with chronic ischemic stroke and demonstrated an excellent safety profile of itMSCs.
  • We hope to bring this medication to patients with this debilitating condition,” said Dr. Lev Verkh, Chief Regulatory and Clinical Development Officer.
  • “Unlike other stroke trials using stem cells, this is the first clinical trial of its kind, evaluating Stemedica’s itMSCs.

EQS-News: EKPO to develop and supply fuel cell stacks for a European OEM

Retrieved on: 
Thursday, February 2, 2023
Hydrogen, PEM, Gesellschaft mit beschränkter Haftung, Oxygen, MEA, ElringKlinger, OEM, Horizon Fuel Cell Technologies, Research, Plastic Omnium, Comment, Electric battery

Dettingen/Erms (Germany), February 02, 2023 +++ EKPO Fuel Cell Technologies GmbH (EKPO) has secured a contract from a European car manufacturer for fuel cell stacks to be fitted to a future series production vehicle.

Key Points: 
  • Dettingen/Erms (Germany), February 02, 2023 +++ EKPO Fuel Cell Technologies GmbH (EKPO) has secured a contract from a European car manufacturer for fuel cell stacks to be fitted to a future series production vehicle.
  • Achieving in excess of 6.0 kW/l in the cell block, the existing EKPO stack family is seen as a market benchmark.
  • Through its parent company ElringKlinger, EKPO has been actively pursuing fuel cell research and development for around 20 years.
  • For further information, please contact on behalf of EKPO Fuel Cell Technologies: